Regular ArticleCerebrospinal Fluid Amyloid β1–42 Levels in the Mild Cognitive Impairment Stage of Alzheimer's Disease
References (18)
- et al.
Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
Neurosci. Lett.
(1999) - et al.
Lancet
(1991) - et al.
Mild cognitive impairment. An early stage of Alzheimer's disease?
J. Neural Transm.
(1998) - et al.
Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease
Ann. Neurol.
(1995) - et al.
Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease
Neurology
(1997) - et al.
Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease
J. Neurosci.
(1996) - et al.
Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression
Ann. Neurol.
(1999) - et al.
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under auspices of the Department of Health and Human Services Task Force on Alzheimer's disease
Neurology
(1984)
Cited by (92)
CSF Aβ<inf>1–42</inf> but not p-Tau<inf>181</inf> differentiates aMCI from SCI
2018, Brain ResearchCitation Excerpt :Although this study does not differentiate aMCI from SCI, some older studies compared CSF Aβ1–42 levels in general MCI individuals and healthy cognitively people (Herukka et al., 2005; Maruyama et al., 2001). One reported that CSF Aβ1–42 levels did not differ significantly between cognitively normal subjects and MCI groups (Maruyama et al., 2001), and other showed that values of CSF Aβ1–42 were significantly lower in progressive MCI group than in progressive and stable MCI groups (Herukka et al., 2005). The broad variation at the measurements of these biomarkers between studies and laboratories is only one of the difficulties in determining homogenous cutoff points (Tang et al., 2014a).
Assessment of CSF Aβ<inf>42</inf> as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: A meta-analysis of 50 studies
2014, Journal of the Neurological SciencesCitation Excerpt :Furthermore, the Begg's and Egger's test were used to estimate evidence for potential publication bias. Twenty-seven studies presented Aβ42 levels for AD vs MCI [16–42], from which there was a total of 3739 participants (1681 in AD groups, 2058 in MCI groups). Thirteen studies presented Aβ42 levels for AD vs FTD [20,24,37,43–52], from which there was a total of 1172 participants (888 in AD groups, 284 in FTD groups).
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
2011, Alzheimer's and DementiaIncreased plasma levels of lipocalin 2 in mild cognitive impairment
2011, Journal of the Neurological SciencesAn unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels
2010, Experimental NeurologyQuantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates
2023, CPT: Pharmacometrics and Systems Pharmacology
- 1
To whom correspondence and reprint requests should be addressed. Fax: +81-22-717-7186. E-mail: [email protected].